You are here

TOPIC 323 PHASE I; DEVELOPMENT OF RADIATION MODULATORS FOR USE DURING RADIOTHERAP

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N43CA130020
Agency Tracking Number: N43CA130020
Amount: $249,997.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2600 N Stemmons Frwy, Ste 129
DALLAS, TX 75207-
United States
DUNS: 610369535
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DONALD STEWART
 (214) 350-9156
 DSTEWART@OMMSCIENTIFIC.COM
Business Contact
 DONALD STEWART
Phone: (214) 350-9156
Email: DSTEWART@OMMSCIENTIFIC.COM
Research Institution
N/A
Abstract

Radiation insensitive tumors that become radiation resistant are often also invasive, metastatic, and responsible for most cancer deaths. Here, the long term objective is to complete clinical evaluation of an inhibitor of a new target (V-ATPase) that sensitizes tumors but not healthy tissues to radiation and inhibits multiple aspects of tumor metabolism and therapeutic resistance. Development of the inhibitor begins with its preparation and determination of its lifetime in cell culture media and in preparation of stable, concentrated dosing solutions suitable for continuous infusion. Next, it will be determined if that SaliPhe and SaliPhe plus ionizing radiation (IR) are much more toxic to a panel of non-small cell lung cancer (NSCLC) cell lines, than to a panel of normal human bronchial epithelial cells (HBEC). To probe the mechanisms of the differences, genomic expression studies and metabolism studies will be performed on untreated cells of both panels and treated with SaliPhe and with SaliPhe + IR.From these data, two NSCLC cell lines will be evaluated in tumor models where the effect of SaliPhe alone, IR, and SaliPhe+ IR are observed. Compelling data will propel further development of SaliPhe as a radiation sensitizer and plan set forth for further development and commercialization. PUBLIC HEALTH RELEVANCE

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government